convalescent plasma treatment - versus potential COVID-19 treatments - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.60 [0.27, 1.34]< 10%3 studies (3/-)89.4 %some concernnot evaluable moderatecrucial-
clinical improvement 1.11 [0.75, 1.62]> 110%2 studies (2/-)69.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
clinical worsening 0.27 [0.06, 1.25]< 10%1 study (1/-)95.3 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

serious adverse events 0.96 [0.29, 3.17]< 10%1 study (1/-)52.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

This meta-analysis covered 2 pathologies: 95,94,90,91 95, 91